AZ6197
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 17, 2018
Selumetinib-based therapy in uveal melanoma patient-derived xenografts
(AACR 2018)
- "Selumetinib was administered alone or combined with chemotherapies (dacarbazine and docetaxel) or targeted therapies: the ERK inhibitor, AZ6197 and the mTORC1/2 inhibitor, vistusertib (AZD2014). Our data suggest that ERK and mTORC1/2 targeting could represent promising therapeutic approaches for the treatment of metastatic UM patients."
Clinical • Ocular Melanoma
1 to 1
Of
1
Go to page
1